Pipeline
UNION has built a differentiated mid-to late-stage clinical pipeline with drug candidates in large therapeutic areas.
Menu
Preclinical
Phase I
Phase IIa
Phase IIb
Phase III
Orismilast - Immunodermatology
Other
*) Innovent Biologics has exclusive rights to oral orismilast and an option on topical orismilast for China, HK, Taiwan and Macau; UNION retains remaining worldwide rights.
Expanded access policy to be found here.
